FDA Compounding Enforcement 2026: What's Actually Happening to 503A/503B Pharmacies
The FDA escalated enforcement against certain GLP-1 compounders in early 2026. Warning letters went out, some operations shut down. But the legal compounding pathway remains intact. Here's the current regulatory landscape.
The FDA's relationship with GLP-1 compounding has been the defining regulatory story of 2025–2026. After years of relatively hands-off enforcement, the agency accelerated action against compounders it deemed non-compliant — while legitimate 503A and 503B pharmacies continue to operate legally.
The Legal Framework
Compounded semaglutide and tirzepatide exist in a specific legal space defined by two sections of the Federal Food, Drug, and Cosmetic Act:
- Section 503A: Traditional compounding pharmacies. Fill individual prescriptions from licensed prescribers. Regulated by state pharmacy boards. Not required to be registered with FDA or follow cGMP.
- Section 503B: Outsourcing facilities. Can produce compounded drugs without individual prescriptions. Must register with FDA, are subject to FDA inspection, and must follow current good manufacturing practices (cGMP). Higher regulatory standard.
Both pathways allow compounding when the brand-name drug is in shortage OR when the compounded version is "essentially a copy" but with a meaningful difference (e.g., combined with B12 or in a different concentration).
2026 Enforcement Actions
The FDA has taken several categories of action:
- Warning letters to specific telehealth platforms: MEDVi received an FDA warning letter in February 2026. The letter cited concerns about marketing practices and product claims. MEDVi continues to operate but any content featuring MEDVi must include the warning letter disclosure.
- Cease and desist to non-registered compounders: Several online sellers without proper 503A or 503B licensing were ordered to stop selling compounded semaglutide. These were primarily drop-shipping operations without a legitimate pharmacy.
- Shortage status changes: The FDA's shortage list — which determines whether compounding is permissible for drugs that are not in shortage — has been a moving target. As brand-name supply stabilizes, the legal basis for some compounding narrows.
What's Still Legal
Legitimate compounding of GLP-1 medications remains legal under specific conditions:
- A licensed physician prescribes the compounded medication after a clinical evaluation
- A state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility prepares the medication
- The compounded product is not an "essentially a copy" that violates the FDCA (typically achieved through meaningful differentiation)
- The compounding is performed in compliance with USP standards for sterile preparations
How to Verify Your Provider's Legitimacy
- LegitScript certification: Third-party verification of pharmacy and telehealth legitimacy. Providers like GobyMeds carry this certification.
- 503B registration: Searchable on the FDA's outsourcing facility database
- State pharmacy license: Verifiable through the relevant state board of pharmacy
- Physician involvement: Legitimate providers require a medical consultation before prescribing. If you can order semaglutide without any physician interaction, that's illegal.
The Bottom Line
The FDA's 2026 enforcement has targeted the margins — unlicensed operators and misleading marketing claims — not the legitimate compounding pathway. 503A and 503B pharmacies operating within the law continue to compound GLP-1 medications. The enforcement has actually been beneficial for consumers by removing the worst actors from the market. Verify your provider's pharmacy licensing and you're on solid ground.
Sources
- FDA. Section 503A and 503B, Federal Food, Drug, and Cosmetic Act.
- FDA. Warning letter to MEDVi. February 2026.
- FDA. Drug Shortage Database. semaglutide/tirzepatide entries. Accessed May 2026.
- FDA. Outsourcing Facility Registration database. fda.gov.
- LegitScript. Pharmacy certification standards. legitscript.com.